SAB Biotherapeutics (SABS) EBITDA (2021 - 2026)

SAB Biotherapeutics (SABS) has 6 years of EBITDA data on file, last reported at -$20.0 million in Q1 2026.

• Quarterly EBITDA fell 85.64% year-over-year to -$20.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$58.2 million (down 37.56% YoY) and the FY2025 annual result came in at -$49.0 million, down 14.08% from the prior year.
• EBITDA fell to -$20.0 million in Q1 2026, from -$15.8 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$5.3 million in Q3 2023 to a low of -$20.0 million in Q1 2026.
• A 5-year average of -$10.5 million and a median of -$10.0 million in 2024 frame the typical range for EBITDA.
• Annual changes were most pronounced in 2022 — EBITDA tumbled 924.07% — and 2024, when it soared 46.97%.
• Tracing SABS's EBITDA over 5 years: stood at -$7.9 million in 2022, then sank by 140.12% to -$18.9 million in 2023, then soared by 46.97% to -$10.0 million in 2024, then tumbled by 57.56% to -$15.8 million in 2025, then slipped by 26.81% to -$20.0 million in 2026.
• The last three EBITDA figures came in at -$20.0 million (Q1 2026), -$15.8 million (Q4 2025), and -$12.7 million (Q3 2025), per Business Quant data.